Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.

@article{GambacortiPasserini2000RoleOA,
  title={Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.},
  author={C Gambacorti-Passerini and R Barni and P le Coutre and M Zucchetti and G Cabrita and Loredana Cleris and F Rossi and E Gianazza and Josef Brueggen and R Cozens and P Pioltelli and E Pogliani and G Corneo and Franca Formelli and Maurizio D'Incalci},
  journal={Journal of the National Cancer Institute},
  year={2000},
  volume={92 20},
  pages={1641-50}
}
  • C Gambacorti-Passerini, R Barni, +12 authors Maurizio D'Incalci
  • Published 2000 in Journal of the National Cancer Institute
BACKGROUND Chronic myeloid leukemia is caused by a chromosomal translocation that results in an oncogenic fusion protein, Bcr-Abl. Bcr-Abl is a tyrosine kinase whose activity is inhibited by the antineoplastic drug STI571. This drug can cure mice given an injection of human leukemic cells, but treatment ultimately fails in animals that have large tumors when treatment is initiated. We created a mouse model to explore the mechanism of resistance in vivo. METHODS Nude mice were injected with… CONTINUE READING